ST6GAL1 and ovarian carcinoma: Similar results were observed in ovarian cancer cells by Britain et al., providing the first evidence that sialylation of EGFR by ST6GAL1 promotes EGFR activation and consequent resistance to gefitinib-mediated cell death [109].